

# World Journal of *Gastrointestinal Oncology*

*World J Gastrointest Oncol* 2024 April 15; 16(4): 1091-1675



### EDITORIAL

- 1091** Parallel pathways: A chronicle of evolution in rectal and breast cancer surgery  
*Pesce A, Fabbri N, Iovino D, Feo CV*
- 1097** Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: Where we are now  
*Sukowati CHC, Jayanti S, Turyadi T, Muljono DH, Tiribelli C*

### REVIEW

- 1104** Novel milestones for early esophageal carcinoma: From bench to bed  
*Qi JH, Huang SL, Jin SZ*
- 1119** Colorectal cancer screening: A review of current knowledge and progress in research  
*Lopes SR, Martins C, Santos IC, Teixeira M, Gamito É, Alves AL*
- 1134** New avenues for the treatment of immunotherapy-resistant pancreatic cancer  
*Silva LGO, Lemos FFB, Luz MS, Rocha Pinheiro SL, Calmon MDS, Correa Santos GL, Rocha GR, de Melo FF*

### MINIREVIEWS

- 1154** Present situation of minimally invasive surgical treatment for early gastric cancer  
*Li CY, Wang YF, Luo LK, Yang XJ*
- 1166** Mixed neuroendocrine non-neuroendocrine neoplasms in gastroenteropancreatic tract  
*Díaz-López S, Jiménez-Castro J, Robles-Barraza CE, Ayala-de Miguel C, Chaves-Conde M*
- 1180** Esophageal cancer screening, early detection and treatment: Current insights and future directions  
*Qu HT, Li Q, Hao L, Ni YJ, Luan WY, Yang Z, Chen XD, Zhang TT, Miao YD, Zhang F*

### ORIGINAL ARTICLE

#### Retrospective Cohort Study

- 1192** Pre-operative enhanced magnetic resonance imaging combined with clinical features predict early recurrence of hepatocellular carcinoma after radical resection  
*Chen JP, Yang RH, Zhang TH, Liao LA, Guan YT, Dai HY*
- 1204** Clinical analysis of multiple primary gastrointestinal malignant tumors: A 10-year case review of a single-center  
*Zhu CL, Peng LZ*

**Retrospective Study**

- 1213** Predictive model for non-malignant portal vein thrombosis associated with cirrhosis based on inflammatory biomarkers  
*Nie GL, Yan J, Li Y, Zhang HL, Xie DN, Zhu XW, Li X*
- 1227** Predictive modeling for postoperative delirium in elderly patients with abdominal malignancies using synthetic minority oversampling technique  
*Hu WJ, Bai G, Wang Y, Hong DM, Jiang JH, Li JX, Hua Y, Wang XY, Chen Y*
- 1236** Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma  
*Ma KP, Fu JX, Duan F, Wang MQ*
- 1248** Should we perform sigmoidoscopy for colorectal cancer screening in people under 45 years?  
*Leong W, Guo JQ, Ning C, Luo FF, Jiao R, Yang DY*
- 1256** Computed tomography-based radiomics diagnostic approach for differential diagnosis between early- and late-stage pancreatic ductal adenocarcinoma  
*Ren S, Qian LC, Cao YY, Daniels MJ, Song LN, Tian Y, Wang ZQ*
- 1268** Prognostic analysis of related factors of adverse reactions to immunotherapy in advanced gastric cancer and establishment of a nomogram model  
*He XX, Du B, Wu T, Shen H*

**Clinical Trials Study**

- 1281** Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers  
*Bao ZH, Hu C, Zhang YQ, Yu PC, Wang Y, Xu ZY, Fu HY, Cheng XD*

**Observational Study**

- 1296** Computed tomography radiogenomics: A potential tool for prediction of molecular subtypes in gastric stromal tumor  
*Yin XN, Wang ZH, Zou L, Yang CW, Shen CY, Liu BK, Yin Y, Liu XJ, Zhang B*
- 1309** Application of texture signatures based on multiparameter-magnetic resonance imaging for predicting microvascular invasion in hepatocellular carcinoma: Retrospective study  
*Nong HY, Cen YY, Qin M, Qin WQ, Xie YX, Li L, Liu MR, Ding K*
- 1319** Causal roles of gut microbiota in cholangiocarcinoma etiology suggested by genetic study  
*Chen ZT, Ding CC, Chen KL, Gu YJ, Lu CC, Li QY*
- 1334** Is recovery enhancement after gastric cancer surgery really a safe approach for elderly patients?  
*Li ZW, Luo XJ, Liu F, Liu XR, Shu XP, Tong Y, Lv Q, Liu XY, Zhang W, Peng D*
- 1344** Establishment of a cholangiocarcinoma risk evaluation model based on mucin expression levels  
*Yang CY, Guo LM, Li Y, Wang GX, Tang XW, Zhang QL, Zhang LF, Luo JY*

- 1361** Effectiveness of fecal DNA syndecan-2 methylation testing for detection of colorectal cancer in a high-risk Chinese population

*Luo WF, Jiao YT, Lin XL, Zhao Y, Wang SB, Shen J, Deng J, Ye YF, Han ZP, Xie FM, He JH, Wan Y*

#### Clinical and Translational Research

- 1374** Clinical and socioeconomic determinants of survival in biliary tract adenocarcinomas

*Sahyoun L, Chen K, Tsay C, Chen G, Protiva P*

- 1384** Risk factors, prognostic factors, and nomograms for distant metastasis in patients with diagnosed duodenal cancer: A population-based study

*Shang JR, Xu CY, Zhai XX, Xu Z, Qian J*

- 1421** NOX4 promotes tumor progression through the MAPK-MEK1/2-ERK1/2 axis in colorectal cancer

*Xu YJ, Huo YC, Zhao QT, Liu JY, Tian YJ, Yang LL, Zhang Y*

#### Basic Study

- 1437** Curcumin inhibits the growth and invasion of gastric cancer by regulating long noncoding RNA AC022424.2

*Wang BS, Zhang CL, Cui X, Li Q, Yang L, He ZY, Yang Z, Zeng MM, Cao N*

- 1453** MicroRNA-298 determines the radio-resistance of colorectal cancer cells by directly targeting human dual-specificity tyrosine(Y)-regulated kinase 1A

*Shen MZ, Zhang Y, Wu F, Shen MZ, Liang JL, Zhang XL, Liu XJ, Li XS, Wang RS*

- 1465** Human  $\beta$ -defensin-1 affects the mammalian target of rapamycin pathway and autophagy in colon cancer cells through long non-coding RNA TCONS\_00014506

*Zhao YX, Cui Y, Li XH, Yang WH, An SX, Cui JX, Zhang MY, Lu JK, Zhang X, Wang XM, Bao LL, Zhao PW*

- 1479** FAM53B promotes pancreatic ductal adenocarcinoma metastasis by regulating macrophage M2 polarization

*Pei XZ, Cai M, Jiang DW, Chen SH, Wang QQ, Lu HM, Lu YF*

- 1500** Transcriptome sequencing reveals novel biomarkers and immune cell infiltration in esophageal tumorigenesis

*Sun JR, Chen DM, Huang R, Wang RT, Jia LQ*

- 1514** Construction of CDKN2A-related competitive endogenous RNA network and identification of GAS5 as a prognostic indicator for hepatocellular carcinoma

*Pan Y, Zhang YR, Wang LY, Wu LN, Ma YQ, Fang Z, Li SB*

- 1532** Two missense STK11 gene variations impaired LKB1/adenosine monophosphate-activated protein kinase signaling in Peutz-Jeghers syndrome

*Liu J, Zeng SC, Wang A, Cheng HY, Zhang QJ, Lu GX*

- 1547** Long noncoding RNAs HAND2-AS1 ultrasound microbubbles suppress hepatocellular carcinoma progression by regulating the miR-873-5p/tissue inhibitor of matrix metalloproteinase-2 axis

*Zou Q, Wang HW, Di XL, Li Y, Gao H*

- 1564** Upregulated lncRNA PRNT promotes progression and oxaliplatin resistance of colorectal cancer cells by regulating HIPK2 transcription

*Li SN, Yang S, Wang HQ, Hui TL, Cheng M, Zhang X, Li BK, Wang GY*

### SYSTEMATIC REVIEWS

- 1578** Prognosis value of heat-shock proteins in esophageal and esophagogastric cancer: A systematic review and meta-analysis

*Nakamura ET, Park A, Pereira MA, Kikawa D, Tustumi F*

- 1596** Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review

*Farooq HZ, James M, Abbott J, Oyibo P, Divall P, Choudhry N, Foster GR*

### META-ANALYSIS

- 1613** Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers

*Zhang XM, Yang T, Xu YY, Li BZ, Shen W, Hu WQ, Yan CW, Zong L*

- 1626** Success rate of current human-derived gastric cancer organoids establishment and influencing factors: A systematic review and meta-analysis

*Jiang KL, Wang XX, Liu XJ, Guo LK, Chen YQ, Jia QL, Yang KM, Ling JH*

### CASE REPORT

- 1647** Pathologically successful conversion hepatectomy for advanced giant hepatocellular carcinoma after multidisciplinary therapy: A case report and review of literature

*Chu JH, Huang LY, Wang YR, Li J, Han SL, Xi H, Gao WX, Cui YY, Qian MP*

- 1660** Clinical pathological characteristics of "crawling-type" gastric adenocarcinoma cancer: A case report

*Xu YW, Song Y, Tian J, Zhang BC, Yang YS, Wang J*

- 1668** Primary pancreatic peripheral T-cell lymphoma: A case report

*Bai YL, Wang LJ, Luo H, Cui YB, Xu JH, Nan HJ, Yang PY, Niu JW, Shi MY*

**ABOUT COVER**

Peer Reviewer of *World Journal of Gastrointestinal Oncology*, Lie Zheng, Director, Professor, Department of Gastroenterology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an 730000, Shaanxi Province, China. xinliwen696@126.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, *etc.*

**INDEXING/ABSTRACTING**

The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJGO as 3.0; IF without journal self cites: 2.9; 5-year IF: 3.0; Journal Citation Indicator: 0.49; Ranking: 157 among 241 journals in oncology; Quartile category: Q3; Ranking: 58 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2022 is 4.1 and Scopus CiteScore rank 2022: Gastroenterology is 71/149; Oncology is 197/366.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Xiang-Di Zhang; Production Department Director: Xiang Li; Cover Editor: Jia-Ru Fan.

**NAME OF JOURNAL**

*World Journal of Gastrointestinal Oncology*

**ISSN**

ISSN 1948-5204 (online)

**LAUNCH DATE**

February 15, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Monjur Ahmed, Florin Burada

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

**PUBLICATION DATE**

April 15, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



Basic Study

# MicroRNA-298 determines the radio-resistance of colorectal cancer cells by directly targeting human dual-specificity tyrosine(Y)-regulated kinase 1A

Mei-Zhu Shen, Yong Zhang, Fang Wu, Mei-Zhen Shen, Jun-Lin Liang, Xiao-Long Zhang, Xiao-Jian Liu, Xin-Shu Li, Ren-Sheng Wang

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): 0  
Grade C (Good): C, C  
Grade D (Fair): 0  
Grade E (Poor): 0

**P-Reviewer:** Ahn KS, South Korea; Buhrmann C, Germany

**Received:** December 5, 2023

**Peer-review started:** December 5, 2023

**First decision:** December 18, 2023

**Revised:** December 31, 2023

**Accepted:** February 2, 2024

**Article in press:** February 2, 2024

**Published online:** April 15, 2024



**Mei-Zhu Shen, Yong Zhang, Fang Wu, Ren-Sheng Wang**, Department of Radiotherapy, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China

**Mei-Zhen Shen**, Department of Radiotherapy, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi Zhuang Autonomous Region, China

**Jun-Lin Liang, Xiao-Long Zhang, Xiao-Jian Liu**, Department of Colorectal Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China

**Xin-Shu Li**, Department of Clinical Medicine, Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China

**Corresponding author:** Ren-Sheng Wang, PhD, Doctor, Department of Radiotherapy, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Qingxiu District, Nanning 530021, Guangxi Zhuang Autonomous Region, China. [13807806008@163.com](mailto:13807806008@163.com)

## Abstract

### BACKGROUND

Radiotherapy stands as a promising therapeutic modality for colorectal cancer (CRC); yet, the formidable challenge posed by radio-resistance significantly undermines its efficacy in achieving CRC remission.

### AIM

To elucidate the role played by microRNA-298 (miR-298) in CRC radio-resistance.

### METHODS

To establish a radio-resistant CRC cell line, HT-29 cells underwent exposure to 5 gray ionizing radiation that was followed by a 7-d recovery period. The quantification of miR-298 levels within CRC cells was conducted through quantitative RT-PCR, and protein expression determination was realized through Western blotting. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay and proliferation by clonogenic assay. Radio-induced apoptosis was discerned through flow cytometry analysis.



## RESULTS

We observed a marked upregulation of miR-298 in radio-resistant CRC cells. MiR-298 emerged as a key determinant of cell survival following radiation exposure, as its overexpression led to a notable reduction in radiation-induced apoptosis. Intriguingly, miR-298 expression exhibited a strong correlation with CRC cell viability. Further investigation unveiled human dual-specificity tyrosine(Y)-regulated kinase 1A (DYRK1A) as miR-298's direct target.

## CONCLUSION

Taken together, our findings underline the role played by miR-298 in bolstering radio-resistance in CRC cells by means of DYRK1A downregulation, thereby positioning miR-298 as a promising candidate for mitigating radio-resistance in CRC.

**Key Words:** MicroRNA-298; Human dual-specificity tyrosine(Y)-regulated kinase 1A; Colorectal cancer; Radio-resistance; p53 binding protein 1

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Our findings indicate that microRNA-298 (miR-298) is upregulated in radio-resistant colorectal cancer (CRC) cells. Overexpression of miR-298 leads to decreased human dual-specificity tyrosine(Y)-regulated kinase 1A expression, ultimately enhancing the radio-resistance of CRC cells.

**Citation:** Shen MZ, Zhang Y, Wu F, Shen MZ, Liang JL, Zhang XL, Liu XJ, Li XS, Wang RS. MicroRNA-298 determines the radio-resistance of colorectal cancer cells by directly targeting human dual-specificity tyrosine(Y)-regulated kinase 1A. *World J Gastrointest Oncol* 2024; 16(4): 1453-1464

**URL:** <https://www.wjgnet.com/1948-5204/full/v16/i4/1453.htm>

**DOI:** <https://dx.doi.org/10.4251/wjgo.v16.i4.1453>

## INTRODUCTION

Malignant lesions arising in the colorectal mucosal epithelium give rise to colorectal cancer (CRC), a pervasive and life-threatening malady worldwide. Notably, neoadjuvant irradiation confers substantial advantages to individuals afflicted with CRC in comparison to surgical intervention alone. Research has demonstrated that following a course of five brief radiotherapy sessions delivering 5 gray (Gy) each, overall survival rates ascended from 30% to 38%, accompanied by a notable drop in local recurrence rates from 26% to 9%[1,2]. While radiotherapy stands as a highly efficacious therapeutic approach, the inherent radio-resistance exhibited by tumor cells frequently emerges as a formidable impediment to its effectiveness[3].

DNA double-stranded breaks (DSBs) represent the gravest form of damage inflicted upon chromatin by ionizing radiation (IR). The extent of DNA damage induced by IR varies depending on factors such as radiation dosage, cellular sensitivity to radiation, and DNA repair capabilities[4,5]. The generation of DSBs within specific genomic regions triggers histone H2AX phosphorylation near the injury site, giving rise to the formation of what are commonly known as γH2AX foci[6]. Within these lesions, a complex network interconnecting various biochemical pathways has evolved in cells to neutralize permanent DSB damage, facilitating lesion removal and the restoration of DNA integrity. The principal pathways encompass canonical non-homologous end-joining (NHEJ)[7], alternative NHEJ[8], and homologous recombination[9]. Activation of these DNA repair mechanisms is selectively driven by the nature of the DNA damage, cell cycle phases, chromatin configuration at the site of damage, DSB characteristics, and potentially other factors[4]. Human dual-specificity tyrosine(Y)-regulated kinase 1A (DYRK1A) belongs to a family of genetically conserved protein kinases that encode a critical region of chromosome 21 associated with Down syndrome (DS)[10]. The loss of one copy of the *DYRK1A* gene, or intragenic deletion, has been linked to syndromes featured by microcephaly and severe intellectual disability [11]. Moreover, a mouse model with trisomy of the *DYRK1A* gene was discovered to exhibit certain phenotypic characteristics reminiscent of DS[12]. DYRK1A has also been suggested to participate in governing the recruitment of the tumor suppressor p53 binding protein 1 (53BP1) to DNA damage sites, partly by means of its interaction with ring finger protein 169 (RNF169)[13].

MicroRNAs (miRNAs) constitute a highly conserved family of small, non-coding RNAs that post-transcriptionally control gene expression by facilitating the degradation or impeding the translation of their target mRNAs. A mounting body of evidence underscores the involvement of miRNAs in a wide spectrum of both physiological and pathological processes[14]. Accumulating evidence has linked miR-298 dysregulation to CRC development, with miR-298 overexpression demonstrated to accelerate CRC cell proliferation and metastasis through the targeting of phosphatase and tensin homolog[15]. Yet, it remains to clarify the precise role played by miR-298 in the radio-resistance of CRC cells. Herein, we generated a radio-resistant cell strain and utilized it to scrutinize the genetic alterations induced by radiation that are associated with radio-resistance. Furthermore, we investigated the involvement of miR-298 in radio-resistance



and revealed that it modulates radio-resistance in CRC cells by targeting DYRK1A.

## MATERIALS AND METHODS

### Cell cultivation and irradiation

We purchased CRC HT-29 cells from the American Type Culture Collection and maintained them in a fetal bovine serum (10%; Gibco; Thermo Fisher Scientific, Inc.) and penicillin-streptomycin (1%)-supplemented Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific) in a humidified atmosphere with the temperature maintained at 37 °C and 5% CO<sub>2</sub> in air. They were then seeded in 60 mm culture dishes and exposed to a single dose of 5 Gy radiation using a 60 CO source.

To establish a radiation-resistant CRC cell line, the parental cells underwent a series of treatments. HT-29 cells were planted in 60 mm culture dishes ( $4 \times 10^3$  cells/dish) for IR at a dose of 5 Gy, followed by a 7-d recovery period. This process was repeated 24 times, resulting in a cumulative radiation dose of 120 Gy.

### Western blotting

After cellular proteins isolation using a Protease Inhibitor Cocktail and Protein Phosphatase Inhibitor (Beijing Solarbio Science & Technology Co., Ltd.)-supplemented Radio-Immunoprecipitation Assay (RIPA) buffer (Gibco; Thermo Fisher Scientific), the protein samples were loaded onto a sodium dodecyl sulfate polyacrylamide gel and subsequently blotted onto a PVDF membrane. Primary antibodies (Abs) were applied and incubated overnight in 5% bovine serum albumin at 4 °C. Western blotting analysis was conducted using ImageJ software (Bio-Rad Laboratories, Inc.). The primary Abs used were  $\beta$ -actin Ab (1:2000, 3700S, Cell Signaling Technology, Inc.), ATM Ab (1:2000, ab201022, Abcam), p-ATM Ab (1:1000, ab81292, Abcam), cleaved caspase-3 Ab (1:1500, ab32042, Abcam), cleaved caspase-9 Ab (1:1500, ab2324, Abcam), 53BP1 Ab (1:1000, ab175933, Abcam), H2AX Ab (1:1000, 7631S, Cell Signaling Technology), and p-H2AX Ab (1:500, 9718S, Cell Signaling Technology). For secondary Abs, the following were used: HRP-linked anti-mouse IgG (1:8000, 7076P2) and HRP-linked anti-rabbit IgG (1:5000, 7074P2), both from Cell Signaling Technology.

### RNA analysis

Total RNA was meticulously extracted and purified from HT-29 cells following the precise guidelines provided by TRIzol<sup>®</sup> reagent (Thermo Fisher Scientific), followed by skillful reverse-transcription of it into cDNA at a temperature of 37 °C for 15 min, employing the PrimeScript RT Master Mix cDNA synthesis system (Bio-Rad Laboratories). A highly accurate qPCR analysis was then conducted utilizing SYBR Green (Bio-Rad Laboratories).

The primers employed were as follows: miR-298-forward: 5'-GAAGCAGGGAGGTTCTC-3'; miR-298-reverse: 5'-GAACATGTCTGCGTATCTC-3'.

### Transfection and plasmid constructions

All transfection experiments were meticulously conducted using the highly effective Effectene Transfection Reagent (Qiagen GmbH), strictly following its meticulously detailed recommendations. The essential reagents, including DYRK1A siRNA (si-DYRK1A), miR-298 mimic, miR-298 inhibitor, and the negative control (NC), were all procured from the esteemed supplier Gene Pharma (Shanghai, China). Moreover, for the purpose of this study, the cDNA corresponding to human DYRK1A was skillfully amplified through PCR and subsequently integrated into the pcDNA3.0 empty vector (Thermo Fisher Scientific) to meticulously engineer the pcDNA-DYRK1A vector.

### Generation of stable cell lines

For the generation of miR-298-overexpressing HT-29 cell lines, we employed human pre-miRNA expression constructs, namely lenti-miR-298 (MI0005523), which were thoughtfully procured from System Biosciences. In addition, we used an anti-miR scramble control lentiviral vector (scramble) for control purposes. The methodology involved infecting HT-29 cells with lentiviral particles carrying the miR-298 encoding sequence. To establish stable cell lines expressing miR-298, a prudent selection process using puromycin was meticulously conducted.

### CRC subcutaneous tumor modeling in nude mice

We purchased 6-8 wk-old BALB/c nude mice, all males, from the Animal Experiment Center of Guangxi Medical University. These mice were meticulously maintained in a controlled laboratory environment, featuring a temperature of 23 °C  $\pm$  2 °C, humidity at 50%  $\pm$  5%, and a light/dark (10/14 h) cycle. It's worth noting that approval has been received from the Animal Care and Ethics Committee of Guangxi Medical University, and all the facilities adhered to ethical standards. To induce CRC tumors, we prepared miR-298-overexpressing HT-29 cells as well as cells transfected with scrambled control. After suspension in DMEM (200  $\mu$ L), these cells were injected subcutaneously into the mouse right hind feet. Once the xenografts reached a mean size of 20 mm<sup>3</sup>, the tumor-bearing mice were randomly grouped as follows, each consisting of 5 mice: Scramble-UT: Mice in this group did not receive any treatment; rLV-miR-298-UT: Again, this group of mice did not undergo any treatment; rLV-miR-298-IR: Mice were treated with 5 Gy IR exposure on the 0, 4<sup>th</sup> d, and 8<sup>th</sup> d; rLV-miR-298-IR: Similar to the previous group, these animals were subjected to 5 Gy IR exposure on the 0, 4<sup>th</sup> d, and 8<sup>th</sup> d. Tumor size was regularly assessed by measuring dimensions with calipers on days 0, 4, 8, and 12. The tumor volume for each mouse was calculated using the formula:  $V \text{ (mm}^3\text{)} = 1/6 \pi \times \text{length (mm)} \times \text{width}^2 \text{ (mm}^2\text{)}$ . At the conclusion of the experiment, which took place 20 days after tumor implantation, the mice were euthanized to

carefully excise the tumor, which was then weighed and photographed for analysis.

### Clonogenic assay

HT-29 cells were initially seeded into the wells (4000-8000 cells/well) of 6-well plates. Subsequently, these cells were subjected to IR treatment. After a period of 12 d, colonies that had formed were meticulously fixed using 10% formalin at room temperature for a duration of 10 min. Following this, the colonies were stained with a 0.02% crystal violet solution for another 10 min, also at room temperature. The number of cells within each colony was then quantified under a dissection microscope. The survival fraction was subsequently determined by expressing it as the ratio of the relative plating efficiencies of irradiated cells to non-irradiated cells.

### In vitro cell viability assay

We employed a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay kit (Beijing Solarbio Science & Technology Co., Ltd.) to determine cell viability, with the procedures conducted as per the instructions. Briefly, cells were planted into the wells of 96-well plates and allowed to grow until reaching approximately 75% confluence. After the designated treatment, MTT solution with a concentration of 5 mg/mL was introduced into each well for a 4-h cultivation at 37 °C. DMSO (50 µL) was added to each well after solution removal, followed by absorbance (490 nm) measurement utilizing a microplate reader (Thermo Fisher Scientific).

### Statistical analysis

Quantitative data, derived from a minimum of three independent experiments, are presented in the form the mean  $\pm$  SD. Data obtained from these experiments were subjected to statistical analysis using one-way analysis of variance (ANOVA), followed by Tukey's post hoc tests, with SPSS 22.0 software (IBM Corp.). The presence of statistical significance is indicated by  $P < 0.05$ .

## RESULTS

### MiR-298 enhanced the radiation resistance of CRC cell lines

First, we generated a radio-resistant CRC cell line by exposing HT-29 cells to 120 Gy IR over a two-week treatment. In comparison to the parental cells, HT-29-IR cells exhibited an obvious increase in radio-resistance. To confirm these observed phenotypes, we assessed the survival rate through a clonogenic assay in irradiated HT-29-IR cells. The results demonstrated resistance of HT-29-IR to radiation-induced cell death in comparison to their parental counterparts (Figure 1A). Furthermore, flow cytometry analysis of apoptosis consistently indicated that HT-29-IR cells were highly resistant to radiation-induced apoptotic cell death (Figure 1B). It was found that miR-298 was upregulated in HT-29-IR, suggesting the potential involvement of miR-298 in radio-resistance of CRC (Figure 1C). To explore the role of miR-298, HT-29 cells overexpressing miR-298 and knocking down miR-298 were transfected with miR-298 mimic and miR-298 inhibitor, respectively. Overexpression or knockdown efficiency was confirmed by qPCR (Figure 1D). Notably, clonogenic assay demonstrated increased survival of radiation-exposed HT-29 after overexpressing miR-298, whereas knockdown of miR-298 contributed to the opposite effect on survival versus control group (Figure 1E). Therefore, the results indicated that miR-298 overexpression protected radiation-induced apoptosis.

### MiR-298 reduced radio-sensitivity of CRC tumors


To verify the specificity of the function of miR-298 in radio-resistance, an ectopic (subcutaneous) CRC model in nude mice was generated as described previously[16]. The subcutaneous implantation of scramble-transfected cells resulted in growing tumors, which is suppressed by a single dose of local radiation (Figure 2A). However, the data of tumor size and weight showed that overexpression of miR-298 rendered xenograft more resistance to radiation treatment (Figure 2B). These findings suggested that miR-298 overexpression reduced radio-sensitivity in CRC tumors *in vivo*.

### MiR-298 reduced 53BP1 expression

In response to radiation, DNA damage response proteins such as H2AX, ATM, and 53BP1 were recruited to the double-strand breaks sites. Subsequently, the role played by miR-298 in DNA damage was examined. As shown in Figure 3A, overexpression of miR-298 decreased 53BP1 protein levels, but did not alter the expression of H2AX and ATM. In addition, miR-298 overexpression displayed no notable effects on radiation-induced phosphorylated ATM and H2AX, but reduced 53BP1 expression (Figure 3B). This suggested that miR-298 is required for maintaining 53BP1 expression.


### MiR-298 directly targeted DYRK1A

We utilized TargetScan (URL: <http://www.targetscan.org>) to predict miR-298's potential target genes. The analysis results revealed that, while 53BP1 is not a direct target of miR-298, miR-298 could target DYRK1A (Figure 4A), a gene required for maintaining 53BP1 expression and its subsequent recruitment to DNA damage loci. Further, a luciferase reporter assay was carried out to assess the direct association of miR-298 with DYRK1A. HT-29 cells were co-transfected with DYRK1A-UTR-WT- or DYRK1A-UTR-Mut-containing luciferase reporters along with miR-298 mimics. The luciferase reporter assay results indicated a 51% inhibition of luciferase activity in cells transfected with miR-298 mimic fused to DYRK1A UTR, compared to the NC (Figure 4B). Additionally, DYRK1A expression was reduced in miR-298 mimic group but enhanced in miR-298 inhibitor group (Figure 4C). Compared with the NC group, the expressions of



**Figure 1** MicroRNA-298 overexpression promoted the radiation resistance of colorectal cancer cell strains. A: As demonstrated by clonogenic assay, radiation-resistant cell lines (HT-29-IR) exhibited a notable increase in survival rates compared to the radio-sensitive parental cell lines (HT-29) upon exposure

to radiation treatment; B: Annexin V/PI staining was performed on HT-29 and HT-29-IR exposed to 5 Gy irradiation. The results indicated that HT-29-IR cells were highly resistant to radiation-induced apoptotic cell death than HT-29; C: Real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) was performed to determine microRNA-298 (miR-298) expression in HT-29 and HT-29-IR; D: RT-qPCR was conducted to assess miR-298 levels in HT-29 transfection with either the miR-298 mimic or miR-298 inhibitor; E: HT-29 cells were transfected with miR-298 mimic or miR-298 inhibitor and then exposed to radiation, followed by cell survival assessment by clonogenic assay. <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$ . miR-298: MicroRNA-298; HT-29-IR: Radiation-resistant cell lines; IR: Ionizing radiation.



**Figure 2 MicroRNA-298 overexpression decreases radio-sensitivity in the tumor of ectopic colorectal cancer model.** A and B: Mice were treated with ionizing radiation when tumor volume reached 20 mm<sup>3</sup>, and then tumor growth was monitored for 12 d. Data are mean  $\pm$  SD values from 5 individual mice in each group. Tumor weights were measured after mice were sacrificed on day 20, representative tumors from corresponding treatments groups. The control group (A) was more sensitive to radiation than the microRNA-298 overexpression group (B). <sup>a</sup> $P < 0.05$ ; NS: Not significant. miR-298: MicroRNA-298; UT: Untreated; IR: Ionizing radiation.

53BP1 and DYRK1A proteins in the mimic group were significantly decreased under 5-cy treatment, while the expressions of 53BP1 and DYRK1A proteins in the mimic + pcDNA-DYRK1A group were significantly increased compared with the mimic group. Notably, pcDNA-DYRK1A vector-transfected HT-29 cells were able to rescue the decreased expression of 53BP1 induced by miR-298 overexpression (Figure 4D), suggesting that miR-298 regulates 53BP1 expression in a DYRK1A-dependent manner.


### miR-298 influenced CRC cell radio-sensitivity via DYRK1A

We assessed DYRK1A expression in both HT-29 and HT-29-IR cells *via* Western blotting analysis. Interestingly, DYRK1A was observed to be under-expressed in radio-resistant cells (Figure 5A). To investigate whether DYRK1A expression influences radiation resistance, we transfected HT-29 cells with a pcDNA-DYRK1A vector, with pcDNA empty vector-transfected cells served as controls. According to the clonogenic assay, cells characterized by DYRK1A overexpression exhibited a reduced survival rate (Figure 5B). Furthermore, flow cytometry apoptosis assay results indicated that DYRK1A-transfected HT-29-IR cells displayed increased sensitivity to radiation (Figure 5C). MTT assay identified weakened cell viability in the pcDNA-DYRK1A group versus the control group (Figure 5D), suggesting that DYRK1A may functionally enhance radio-sensitivity. Intriguingly, miR-298 downregulation in HT-29 realized through inhibitor transfection significantly enhanced radiation-induced cleaved-caspase3 and cleaved-caspase9, and this effect was counteracted by DYRK1A silencing (Figure 5E). These results imply that miR-298 reduces radiation-induced CRC cell apoptosis and radio-sensitivity by modulating DYRK1A expression.

## DISCUSSION

Radiotherapy resistance is considered a conundrum to decipher in radiotherapy treatment of CRC. Therefore, a thorough understanding of the mechanism underlying radio-resistance is important to enhance radiotherapy efficacy. After






**Figure 3 MicroRNA-298 overexpression decreases p53 binding protein 1 expression.** A: After scramble or microRNA-298 (miR-298) mimic transfection, HT-29 cells were detected by Western blotting for ATM, H2AX, and p53 binding protein 1 (53BP1) protein levels; B: HT-29 cells were subjected to radiation exposure after scramble or miR-298 mimic transfection. Western blotting was performed to detect the total and phosphorylated ATM, H2AX, and 53BP1 expression. <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$ . miR-298: MicroRNA-298; IR: Ionizing radiation; ATM: Ataxia telangiectasia mutated; H2AX: H2A.X variant histone; 53BP1: p53 binding protein 1.

radiation, some cellular processes begin to repair the damage, whereas cells that fail repair undergo death[17]. In this study, a radiation resistant HT-29 (HT-29-IR) cell strain was established, with which an *in vitro* model was built to study the molecular mechanisms behind radio-resistance. The results showed that caspases activity and apoptosis of HT-29-IR cells decreased after irradiation. Additionally, a connection between high miR-298 expression in tumors and CRC cell radio-resistance was determined.


Indeed, there is compelling evidence that miR-298 is essential in the regulation of various signaling transduction mediators, contributing to cell cycle regulation and tumour survival. For instance, miR-298 showed upregulated expression in prostate cancer tissues than in normal counterparts[18]. Moreover, overexpressing miR-298 reduces hepatocellular carcinoma cell migration and invasiveness by suppressing the Wnt/ $\beta$ -catenin axis[19]. Furthermore, miR-298 inhibited pro-apoptotic Bcl-2-associated X (BAX) protein expression, leading to decreased gastric carcinoma cell apoptosis [20]. Upregulated miR-298 was found in radio-resistant CRC cells in the present study. Overexpressing miR-298 reduced radiation-induced apoptosis. *In vitro* experiment, it was also confirmed the beneficial role: MiR-298 overexpression decreased radio-sensitivity of CRC tumors. The present study showed miR-298 is required for the basal expression of 53BP1, a DNA repair protein that rapidly recruited to the DSB site following exposure to radiation[21]. 53BP1 Localization to DSBs depends on multiple chromatin changes that occur in the vicinity of DNA damage. Studies have



**Figure 4 Human dual-specificity tyrosine(Y)-regulated kinase 1A is microRNA-298's target.** A: A schematic diagram depicts the putative binding loci of microRNA-298 (miR-298) within the 3' untranslated region (3'UTR) of the human dual-specificity tyrosine(Y)-regulated kinase 1A (DYRK1A) gene; B: A luciferase reporter assay was carried out to assess the direct association of miR-298 with DYRK1A in HT-29. These cells were co-transfected with the miR-298 mimic plus a luciferase reporter construct containing either the wild-type (WT) DYRK1A 3'UTR or a mutant (Mut) version that disrupted the putative miR-298 binding sites; C: Following negative control (NC), miR-298 inhibitor, or miR-298 mimic transfection, and Western blotting was carried out to determine DYRK1A protein expression in HT-29 cells; D: HT-29 cells were subjected to NC, or miR-298 mimic transfection, or miR-298 mimic plus pcDNA-DYRK1A vector co-transfection, followed by western blotting determination of DYRK1A and p53 binding protein 1 expressions. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01. miR-298: MicroRNA-298; IR: Ionizing radiation; DYRK1A: Human dual-specificity tyrosine(Y)-regulated kinase 1A; NC: Negative control.

shown that 53BP1 and di-methylation of histone H4 lysine 20 (H4K20me2) is closely related to DNA damage induced by radiation[22,23]. Besides, RNF8 and RNF168, the RING finger E3 ubiquitin ligases, are essential for 53BP1 recruitment[13, 24].

According to predictions from the TargetScan database, miR-298 appears to directly target DYRK1A. Previous research has reported that the knockdown of DYRK1A reduced p53Ser-15 phosphorylation in neurons[25]. DYRK1A plays a part in regulating mitochondrial apoptotic signaling by increasing the levels of mitochondrial apoptotic proteins, including caspase-9/3. Additionally, a study by Laguna *et al*[26] demonstrated the ability of DYRK1A to modulate caspase-9-mediated apoptosis during retinal development. Consistent with prior reports[27], our study reveals that DYRK1A is downregulated in radio-resistant CRC cells. Lan *et al*[28] showed that DYRK1A is a target of radiotherapy sensitization in pancreatic cancer. Their study confirmed that DYRK1A inhibition, used in combination with radiotherapy, increases DNA double-strand breaks and impacts homologous repair, leading to more cancer cell death. Consequently, DYRK1A may function as a tumor suppressor due to its ability to promote radio-sensitivity in CRC cells. This study has shed light on the roles of miR-298 and DYRK1A in CRC cells. To gain a more comprehensive understanding of miR-298's function, clinical analyses should be considered to assess its diagnostic and prognostic value in CRC.



**Figure 5** MicroRNA-298 knockdown regulates radio-induced apoptosis depended on human dual-specificity tyrosine(Y)-regulated kinase 1A expression. A: Western blotting was carried out to examine human dual-specificity tyrosine(Y)-regulated kinase 1A (DYRK1A) levels in HT-29 and HT-29-IR cell



lines; B: HT-29 cells were exposed to radiation following empty vector or pcDNA-DYRK1A vector transfection. Clonogenic assay was performed to assess cell survival; C: HT-29 cells were treated with radiation exposure after empty vector or pcDNA-DYRK1A vector transfection, followed by cell apoptosis examination by Annexin V/PI staining; D: HT-29 cells were treated with radiation exposure after empty vector or pcDNA-DYRK1A vector transfection, and cell viability was then determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay; E: HT-29 cells were transfected with inhibitor, or co-transfected with inhibitor and si-DYRK1A, and then exposed to radiation. Western blotting was carried out to measure cleaved-caspase 3/9 protein levels. \* $P < 0.05$ .

## CONCLUSION

In summary, our findings indicate that miR-298 is upregulated in radio-resistant CRC cells. Overexpression of miR-298 leads to decreased DYRK1A expression, ultimately enhancing the radio-resistance of CRC cells.

## ARTICLE HIGHLIGHTS

### Research background

Radiotherapy stands as a promising therapeutic modality for colorectal cancer (CRC); yet, the formidable challenge posed by radio-resistance significantly undermines its efficacy in achieving CRC remission.

### Research motivation

Radiotherapy can effectively inhibit the proliferation of cancer cells, but a considerable number of CRC patients are still resistant to radiotherapy, and further exploration of potential drug resistance targets is needed to provide a theoretical basis for developing effective treatment strategies to improve response rate.

### Research objectives

To analyze the role of microRNA-298 (miR-298) in the radioresistance of CRC and its molecular mechanism. MiRNAs are involved in a wide range of physiological and pathological processes, and the dysregulation of miR-298 has been shown to be related to the development of CRC. However, the exact role that miR-298 plays in the radioresistance of CRC cells remains to be elucidated.

### Research methods

This study established a radiation-resistant CRC cell line, which exposes HT-29 cells to 5 gray ionizing radiation, followed by a 7-d recovery period. The miR-298 expression level and the biological behavior of HT-29 cells were examined before and after radiotherapy. To explore the radiosensitivity and the expression of downstream target genes in ectopic CRC model tumors after overexpressing miR-298. Dual-luciferase reporter assay for the binding site of DYRK1A with miR-298. Knockdown of miR-298 observed DYRK1A expression and radiation-induced apoptosis were improved in HT-29 cells.

### Research results

We observed a significant upregulation of miR-298 in radioresistant CRC cells. MiR-298 emerged as a key determinant of cell survival after radiation exposure, as its overexpression resulted in a significant reduction in radiation-induced apoptosis. Interestingly, there was a strong correlation between miR-298 expression and CRC cell viability. Further studies revealed DYRK1A as a direct target of miR-298. Taken together, our results highlight the role that miR-298 plays in enhancing radioresistance in CRC cells by downregulation of DYRK1A, thereby positioning miR-298 as a promising candidate gene.

### Research conclusions

This study revealed an important target of CRC resistance to radiotherapy, miR-298, an effect of DYRK1A to enhance radioresistance in CRC cells. This study provides proof of principle for the development of a protocol based on radiotherapy + targeting for CRC.

### Research perspectives

Cancer radiotherapy resistance remains a major challenge for cancer patients. To improve patient outcomes, we need to further understand the mechanisms by which tumor ecosystem tumor cell proliferation, apoptosis, invasion, and migration under the induction of continuous therapy. Analysis of the targets of radiotherapy sensitive/resistant to tumors will help to discover new therapeutic opportunities.

## FOOTNOTES

**Author contributions:** Shen MZ, Zhang Y, and Wang RS conceived and designed the experiments; Wu F, Shen MZ, Liang JL, Zhang XL, Liu XJ, and Li XS performed the experiments; Shen MZ and Wang RS analyzed the data and wrote the manuscript; all authors read and approved the final manuscript.

**Institutional animal care and use committee statement:** This study was reviewed and approved by the Experimental Animal Ethics Committee of the First Affiliated Hospital of Guangxi Medical University (Approval No. 2023-E386-01).

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**Data sharing statement:** The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Ren-Sheng Wang 0000-0002-0768-9344.

**S-Editor:** Chen YL

**L-Editor:** A

**P-Editor:** Yuan YY

## REFERENCES

- Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. *J Clin Oncol* 2005; **23**: 5644-5650 [PMID: 16110023 DOI: 10.1200/JCO.2005.08.144]
- Häfner MF, Debus J. Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives. *Visc Med* 2016; **32**: 172-177 [PMID: 27493944 DOI: 10.1159/000446486]
- Wu QB, Sheng X, Zhang N, Yang MW, Wang F. Role of microRNAs in the resistance of colorectal cancer to chemoradiotherapy. *Mol Clin Oncol* 2018; **8**: 523-527 [PMID: 29556386 DOI: 10.3892/mco.2018.1578]
- Falk M, Hausmann M, Lukášová E, Biswas A, Hildenbrand G, Davidková M, Krasavin E, Kleibl Z, Falková I, Ježková L, Štefančíková L, Ševčík J, Hofer M, Bačíková A, Matula P, Boreyko A, Vachelová J, Michaelidesová A, Kozubek S. Determining Omics spatiotemporal dimensions using exciting new nanoscopy techniques to assess complex cell responses to DNA damage: part A--radiomics. *Crit Rev Eukaryot Gene Expr* 2014; **24**: 205-223 [PMID: 25072147 DOI: 10.1615/critrevukaryotgeneexpr.2014010313]
- Ježková L, Zadneprianec M, Kulikova E, Smirnova E, Bulanova T, Depes D, Falkova I, Boreyko A, Krasavin E, Davidkova M, Kozubek S, Valentova O, Falk M. Particles with similar LET values generate DNA breaks of different complexity and reparability: a high-resolution microscopy analysis of  $\gamma$ H2AX/53BP1 foci. *Nanoscale* 2018; **10**: 1162-1179 [PMID: 29271466 DOI: 10.1039/c7nr06829h]
- Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. *J Biol Chem* 1998; **273**: 5858-5868 [PMID: 9488723 DOI: 10.1074/jbc.273.10.5858]
- Chang HHY, Pannunzio NR, Adachi N, Lieber MR. Non-homologous DNA end joining and alternative pathways to double-strand break repair. *Nat Rev Mol Cell Biol* 2017; **18**: 495-506 [PMID: 28512351 DOI: 10.1038/nrm.2017.48]
- Iliakis G, Murmann T, Soni A. Alternative end-joining repair pathways are the ultimate backup for abrogated classical non-homologous end-joining and homologous recombination repair: Implications for the formation of chromosome translocations. *Mutat Res Genet Toxicol Environ Mutagen* 2015; **793**: 166-175 [PMID: 26520387 DOI: 10.1016/j.mrgentox.2015.07.001]
- Jasin M, Rothstein R. Repair of strand breaks by homologous recombination. *Cold Spring Harb Perspect Biol* 2013; **5**: a012740 [PMID: 24097900 DOI: 10.1101/cshperspect.a012740]
- Birchler JA, Riddle NC, Auger DL, Veitia RA. Dosage balance in gene regulation: biological implications. *Trends Genet* 2005; **21**: 219-226 [PMID: 15797617 DOI: 10.1016/j.tig.2005.02.010]
- Korbel JO, Tirosh-Wagner T, Urban AE, Chen XN, Kasowski M, Dai L, Grubert F, Erdman C, Gao MC, Lange K, Sobel EM, Barlow GM, Aylsworth AS, Carpenter NJ, Clark RD, Cohen MY, Doran E, Falik-Zaccai T, Lewin SO, Lott IT, McGillivray BC, Moeschler JB, Pettenati MJ, Puschel SM, Rao KW, Shaffer LG, Shohat M, Van Riper AJ, Warburton D, Weissman S, Gerstein MB, Snyder M, Korenberg JR. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. *Proc Natl Acad Sci U S A* 2009; **106**: 12031-12036 [PMID: 19597142 DOI: 10.1073/pnas.0813248106]
- Tejedor FJ, Hammerle B. MNB/DYRK1A as a multiple regulator of neuronal development. *FEBS J* 2011; **278**: 223-235 [PMID: 21156027 DOI: 10.1111/j.1742-4658.2010.07954.x]
- Menon VR, Ananthapadmanabhan V, Swanson S, Saini S, Sesay F, Yakovlev V, Florens L, DeCaprio JA, Washburn MP, Dozmorov M, Litovchick L. DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in part through interaction with RNF169. *Cell Cycle* 2019; **18**: 531-551 [PMID: 30773093 DOI: 10.1080/15384101.2019.1577525]
- Qin X, Wang X, Wang Y, Tang Z, Cui Q, Xi J, Li YS, Chien S, Wang N. MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. *Proc Natl Acad Sci U S A* 2010; **107**: 3240-3244 [PMID: 20133739 DOI: 10.1073/pnas.0914882107]
- Arabsorkhi Z, Gharib E, Yaghmoorian Khojini J, Farhadi ME, Nazemalhosseini-Mojarad E, Zali MR. miR-298 plays a pivotal role in colon cancer invasiveness by targeting PTEN. *J Cell Physiol* 2020; **235**: 4335-4350 [PMID: 31621072 DOI: 10.1002/jcp.29310]

- 16 **Wang Y**, Zhao M, Zhao H, Cheng S, Bai R, Song M. MicroRNA-940 restricts the expression of metastasis-associated gene MACC1 and enhances the antitumor effect of Anlotinib on colorectal cancer. *Onco Targets Ther* 2019; **12**: 2809-2822 [PMID: [31114229](#) DOI: [10.2147/OTT.S195364](#)]
- 17 **Hill MA**. Radiation damage to DNA: the importance of track structure. *Radiat Meas* 1999; **31**: 15-23 [PMID: [12025837](#) DOI: [10.1016/s1350-4487\(99\)00090-6](#)]
- 18 **Krell J**, Stebbing J, Carissimi C, Dabrowska AF, de Giorgio A, Frampton AE, Harding V, Fulci V, Macino G, Colombo T, Castellano L. TP53 regulates miRNA association with AGO2 to remodel the miRNA-mRNA interaction network. *Genome Res* 2016; **26**: 331-341 [PMID: [26701625](#) DOI: [10.1101/gr.191759.115](#)]
- 19 **Cao N**, Mu L, Yang W, Liu L, Liang L, Zhang H. MicroRNA-298 represses hepatocellular carcinoma progression by inhibiting CTNND1-mediated Wnt/ $\beta$ -catenin signaling. *Biomed Pharmacother* 2018; **106**: 483-490 [PMID: [29990836](#) DOI: [10.1016/j.biopha.2018.06.135](#)]
- 20 **Zhao H**, Zhao D, Tan G, Liu Y, Zhuang L, Liu T. Bufalin promotes apoptosis of gastric cancer by down-regulation of miR-298 targeting bax. *Int J Clin Exp Med* 2015; **8**: 3420-3428 [PMID: [26064232](#)]
- 21 **Zimmermann M**, de Lange T. 53BP1: pro choice in DNA repair. *Trends Cell Biol* 2014; **24**: 108-117 [PMID: [24094932](#) DOI: [10.1016/j.tcb.2013.09.003](#)]
- 22 **Botuyan MV**, Lee J, Ward IM, Kim JE, Thompson JR, Chen J, Mer G. Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. *Cell* 2006; **127**: 1361-1373 [PMID: [17190600](#) DOI: [10.1016/j.cell.2006.10.043](#)]
- 23 **Pei H**, Zhang L, Luo K, Qin Y, Chesi M, Fei F, Bergsagel PL, Wang L, You Z, Lou Z. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. *Nature* 2011; **470**: 124-128 [PMID: [21293379](#) DOI: [10.1038/nature09658](#)]
- 24 **Mailand N**, Bekker-Jensen S, Fastrup H, Melander F, Bartek J, Lukas C, Lukas J. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. *Cell* 2007; **131**: 887-900 [PMID: [18001824](#) DOI: [10.1016/j.cell.2007.09.040](#)]
- 25 **Park J**, Oh Y, Yoo L, Jung MS, Song WJ, Lee SH, Seo H, Chung KC. Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells. *J Biol Chem* 2010; **285**: 31895-31906 [PMID: [20696760](#) DOI: [10.1074/jbc.M110.147520](#)]
- 26 **Laguna A**, Aranda S, Barallobre MJ, Barhoum R, Fernández E, Fotaki V, Delabar JM, de la Luna S, de la Villa P, Arbonés ML. The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development. *Dev Cell* 2008; **15**: 841-853 [PMID: [19081073](#) DOI: [10.1016/j.devcel.2008.10.014](#)]
- 27 **Zou Y**, Yao S, Chen X, Liu D, Wang J, Yuan X, Rao J, Xiong H, Yu S, Zhu F, Hu G, Wang Y. LncRNA OIP5-AS1 regulates radioresistance by targeting DYRK1A through miR-369-3p in colorectal cancer cells. *Eur J Cell Biol* 2018; **97**: 369-378 [PMID: [29773344](#) DOI: [10.1016/j.ejcb.2018.04.005](#)]
- 28 **Lan B**, Zeng S, Zhang S, Ren X, Xing Y, Kutschick I, Pfeffer S, Frey B, Britzen-Laurent N, Grützmann R, Cordes N, Pilarsky C. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. *Cancers (Basel)* 2022; **14** [PMID: [35053488](#) DOI: [10.3390/cancers14020326](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

